{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-35230162-bremelanotide:v1","objectPathId":"pubmed-pmid-35230162-bremelanotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-35230162-bremelanotide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-35230162-bremelanotide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-35230162-bremelanotide-v1.md"},"story":{"slug":"pubmed-pmid-35230162-bremelanotide","version":1,"domain":"Literature metadata","dateInSource":"2022-03-15","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["bremelanotide"],"peptides":[{"slug":"bremelanotide","url":"https://peptidescanner.com/peptides/bremelanotide/"}]},"claims":[{"id":"headline","text":"Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.","sourceIds":["pubmed-observation-pmid-35230162-2022-03-15-900a59f19c6e"]},{"id":"summary","text":"PubMed lists PMID 35230162 in Journal of women's health (2002) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-25 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-35230162-2022-03-15-900a59f19c6e"]},{"id":"paragraph-1","text":"PubMed lists PMID 35230162 in Journal of women's health (2002) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-25 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-35230162-2022-03-15-900a59f19c6e"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-35230162-2022-03-15-900a59f19c6e"]}],"sources":[{"id":"pubmed-observation-pmid-35230162-2022-03-15-900a59f19c6e","name":"PubMed","sourceClass":"A","title":"Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. · retained source version 1:2022-03-15:current:900a59f19c6ec3c2e62f436cec39fa89c6d909ecedce5887f501d4d6a698b301","url":"https://pubmed.ncbi.nlm.nih.gov/35230162/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"f4477a7a0e994af9af5b3dd324dbae55c0a91e54957345d0355f7244e859217f","tierARecordSha256":"7745f1af96fbb0a7013be435be1c11086692d6e7d83cac7e7e2723aef18cc793"},"integrity":{"algorithm":"sha256","contentSha256":"4b129ab0bd4e9cce753c51399ac8c6234c8b355fe0b6533050f94eb5e2e30b80"}}